Posted on 2/1/19
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of . . .
Posted on 1/31/19
Provident Healthcare Partners Advises Anesthesia Resources In Its Partnership With National Partners In Healthcare
Anesthesia Resources, a leading anesthesia practice in Phoenix's East Valley Area, has joined National Partners in Healthcare, a national healthcare organization delivering best in class anesthesiology . . .
Posted on 1/31/19
MEDITECH Recognized as 2019 Best in KLAS for Acute Care EMR - Canada
Global healthcare research firm KLAS has recognized MEDITECH in its annual Best in KLAS: Software & Services report for the fifth year in a row.In the . . .
Posted on 1/31/19
Alexion and Caelum Biosciences Announce Collaboration
BOSTON & NEW YORK--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is . . .
Posted on 1/31/19
Biogen Looks to 2020
Biogen (NASDAQ:BIIB) posted solid fourth-quarter earnings on Tuesday, but lackluster 2019 revenue guidance leaves investors twiddling their thumbs waiting for growth from the next big hit . . .
Posted on 1/30/19
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December . . .
Posted on 1/30/19
Dewpoint Therapeutics Raises $60 Million
Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.
Posted on 1/29/19
scPharmaceuticals Announces Development Agreement with West Pharmaceutical Services
BURLINGTON, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to . . .
Posted on 1/29/19
Lyndra Therapeutics Raises $55 Million in Series B Financing
Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, today announced it has raised $55 million in Series B financing
Posted on 1/29/19
Harvard Pilgrim Health Care Selects OptumRx as Pharmacy Benefit Manager
WELLESLEY, Mass. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Harvard Pilgrim Health Care, a premier not-for-profit health services company, today announced it has entered into a new, multi-year agreement . . .
Posted on 1/28/19
New Blood Test Helps Clinicians Identify Potentially Life-threatening Ara h 6 Peanut Sensitization
ImmunoCAP Specific IgE blood test for Ara h 6 is part of the line of component assays from Thermo Fisher Scientific that can differentiate between individual . . .
Posted on 1/28/19
Purdue Pharma and Alivio Therapeutics Enter into Partnership
STAMFORD, Conn. & BOSTON--(BUSINESS WIRE)--Purdue Pharma L.P. and Alivio Therapeutics today announced that they have entered into a partnership to advance one of Alivio’s product candidates through . . .
Posted on 1/28/19
PAREXEL Receives Consecutive Recognitions from Forbes and FlexJobs for its Workplace Culture
BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that the Company has once again been recognized for its diverse and flexible . . .
Posted on 1/28/19
Is Vertex Pharmaceuticals a Buy?
Vertex Pharmaceuticals (NASDAQ:VRTX) has proven that it's a winner for investors. The biotech stock more than doubled in 2017. Despite challenging conditions last year with the . . .
Posted on 1/27/19
Corbus Pharmaceuticals Prices Public Offering of Common Stock
Norwood, MA, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company with the industry’s leading pipeline focused . . .
Posted on 1/25/19
Corbus Pharmaceuticals Proposes Public Offering of Common Stock
Norwood, MA, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company with the industry’s leading pipeline focused . . .
Posted on 1/25/19
Bristol-Myers Squibb Co (BMY) Q4 2019 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Bristol-Myers Squibb Co (NYSE:BMY)Q4 2018 Earnings Conference CallJan. 24, 2017, 8:30 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood day, and welcome to . . .
Posted on 1/25/19
CVS Health Announces Transaction With Vitality Re X
CVS Health (NYSE: CVS) today announced that Aetna, a CVS Health business, has entered into a four-year reinsurance arrangement with Vitality Re X Limited as part . . .
Posted on 1/24/19
Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with . . .
Posted on 1/24/19
Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its . . .
Posted on 1/24/19
Berkshire Hathaway: Underappreciated And Undervalued
SummaryEverybody knows that Berkshire is a unique business, but many investors underestimate the true degree to with the company is one of a kind.Access to low-cost . . .
Posted on 1/24/19
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
CAMBRIDGE, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with . . .
Posted on 1/24/19
Selecta Biosciences Prices Public Offering of Common Stock
WATERTOWN, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic . . .
Posted on 1/23/19
CAMP4 Therapeutics Announces Rare Disease Research Collaboration with Alnylam
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CAMP4 Therapeutics today announced a research collaboration with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) focused on identifying new druggable targets to address an undisclosed rare . . .
Posted on 1/23/19
Selecta Biosciences Proposes Public Offering of Common Stock
WATERTOWN, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies . . .

